# HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

> **NCT07647432** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 17 (estimated)

## Conditions studied

- Plasmablastic Lymphoma
- HIV
- Consolidation

## Interventions

- **DRUG:** Elranatamab (Elra)

## Key facts

- **NCT ID:** NCT07647432
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2029-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2026-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647432, "HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*